Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial

BMC Pregnancy and Childbirth

Volumn 15, Issue 1, 2015, Pages

  Koren, Gideon ^a,e   Clark, Shannon ^b,e   Hankins, Gary D ^b,e   Caritis, Steve N ^c,e   Umans, Jason G ^d,e   Miodovnik, Menachem ^d,e   Mattison, Donald R ^e   Matok, Ilan ^a,f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Delaware   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Diclegis; Doxylamine; Nausea and vomiting of pregnancy; Pyridoxine; Safety; Toxicology

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DOXYLAMINE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; PLACEBO; PYRIDOXINE; SERUM ALBUMIN; SODIUM; TRIACYLGLYCEROL; ANTIEMETIC AGENT; DELAYED RELEASE FORMULATION; DICYCLOMINE, DOXYLAMINE, PYRIDOXINE DRUG COMBINATION; DICYCLOVERINE; DRUG COMBINATION; HISTAMINE H1 RECEPTOR ANTAGONIST; VITAMIN B COMPLEX;

ADULT; AMYLASE BLOOD LEVEL; ANTICHOLINERGIC EFFECT; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL EXAMINATION; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELAYED DRUG RELEASE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRY EYE; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; GESTATIONAL AGE; HEADACHE; HEART PALPITATION; HEART RATE; HEMATEMESIS; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; PREGNANCY; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SODIUM BLOOD LEVEL; SOMNOLENCE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG MONITORING; NAUSEA; PREGNANCY COMPLICATIONS; PROCEDURES; TREATMENT OUTCOME; VOMITING;

ADULT; ANTIEMETICS; DELAYED-ACTION PREPARATIONS; DICYCLOMINE; DOUBLE-BLIND METHOD; DOXYLAMINE; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; NAUSEA; PREGNANCY; PREGNANCY COMPLICATIONS; PYRIDOXINE; TREATMENT OUTCOME; VITAMIN B COMPLEX; VOMITING;

EID: 84926665885     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/s12884-015-0488-1     Document Type: Article

References (21)

1. Koren G, Bishai R. Nausea and Vomiting of Pregnancy: State of the art, 2000, vol. 1. Toronto: The Motherisk Program; 2000. p. 5-9.
2. Arsenault MY, Lane CA, MacKinnon CJ, Bartellas E, Cargill YM, Klein MC, et al. SOGC clinical practice guidelines: the management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can. 2002;24(10):817-31.
3. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128-37.
4. Food and Drug administration U.S. Department of Health and Human Services, Public Health Services, Talk Paper. 1983.
5. Federal Register /Vol. 64, No 152/August 9, 1999/Notes, Determination that Bendectin was not withdrawn from sale for reasons of safety or effectiveness.
6. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;86(1):66-70.
7. Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and birth defects. II: ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003;67(2):79-87.
8. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A metaanalysis of the epidemiologic studies. Teratology. 1994;50(1):27-37.
9. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988;22(10):813-24.
10. Diclectin™. Product Monograph. Blainville Quebec, Canada: Duchesnay Inc; 2008.
11. Nulman I, Koren G. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclectin®) and oral solutions of these drugs in healthy women of childbearing age. Can J Clin Pharmacol. 2009;16(3):e400-6. Fall 2009.
12. Koren G, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol. 2010;203(6):571. e1-7.
13. Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186(5):S228-31.
14. Koren G, Piwko C, Ahn E, Boskovic R, Maltepe C, Einarson A, et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol. 2005;25(3):241-4.
15. Ebrahimi N, Maltepe C, Garcia-Bournissen F, Koren G. Nausea and vomiting of pregnancy: using the 24-hour pregnancy-unique quantification of emesis (PUQE-24) scale. J Obstet Gynecol Can. 2009;31:803-7.
16. The American College of Obstetricians and Gynecologists. Nausea and vomiting of pregnancy. ACOG Practice Bulletin No 52. 2004;103(4):803-15.
17. Ornstein M, Einarson A, Koren G. Bendectin/diclectin for morning sickness: a Canadian follow-up of an American tragedy. Reprod Toxicol. 1995;9(1):1-6.
18. Boskovic R, Einarson A, Maltepe C, Wolpin J, Koren G. Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. J Obstet Gynaecol Can. 2003;25(10):830-3.
19. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard dose of doxylamine succinate-pyridoxine hydrochloride (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001;41(8):842-5.
20. Nulman I, Rovet J, Barrera M, Knittel-Keren D, Feldman BM, Koren G. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin. J Pediatr. 2009;155(1):45-50.
21. Redelmeie DAR, May SC, Thiruchelvam D, Barrett JF. Pregnancy and the risk of a traffic crash. CMAJ May 12, 2014 doi:10.1503/cmaj.131650.